Abstract:PD-L1/PD-1 signaling pathway is unarguably the hottest target for developing therapeutics against various types of cancers. With elucidation of crystal structure of PD-1/PD-L1, inhibitors targeting PD-1, PD-L1 or protein-protein interaction between them have been reported. Identification of transcription factors responsible for transcription of mRNA encoding PD-1 and PD-L1 promoted developing inhibitors to downregulate expression of either gene. Elucidation of PD-1 signaling pathway broadened strategies for drug design, for example to interfere recruitment of SHP2 by PD-1. Post-transcription modification (PTM) of phosphorylation, glycosylation, ubiquination and palmitoylation have been reported to modulate the function or homeostasis of proteins of PD-1 or PD-L1. Drugs targeting elements responsible for these PTM have been reported to enhance T cell mediated immunity. Moreover, cleverly designed protein-degrading reagents, either macromolecules or small chemicals (PROTACs) have been tried against PD-1 or PD-L1. In this review we will talk about crystal structure of PD-1/PD-L1, PD-1 signaling pathway, and physiological and pathological roles played by PD-1. Particular attention is paid on strategies for developing drugs targeting PD-1 pathways. For future directions of strategies for developing PD-1/PD-L1 inhibitors, we suggest two realistic fields: bi-functional or multi-functional small molecules; nano-material to deliver siRNAs. With recent identification of many more checkpoints in T cells through genome-wide screening and harnessing the power of nano-materials to pack multiple siRNAs, tumor microenvironment T cell specific mano-materials containing siRNAs against PD-1 and other checkpoints simultaneously could be of particular interest to industry.

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies

The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

The emerging roles of PD-L1 subcellular localization in tumor immune evasion

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion

Optimization of Cancer Immunotherapy on the Basis of Programmed Death Ligand‐1 Distribution and Function

PD-1/PD-L1 pathway: current researches in cancer.

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

A snapshot of the PD-1/PD-L1 pathway

Generation, secretion and degradation of cancer immunotherapy target PD-L1

PD-1 regulation in immune homeostasis and immunotherapy

Regulation of PD-L1 expression in the tumor microenvironment

Strategies for developing PD-1 inhibitors and future directions

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors